Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Metabolic brain disease

• Publication date

  2023-06-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11011-023-01225-3PMID 37335453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness and safety of glibenclamide for stroke: protocol for a systematic review and meta-analysis

  2021cited by this paper
• Thiazolidinediones: An In–Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus

  2021cited by this paper
• WNT Signaling Is a Key Player in Alzheimer's Disease.

  2021cited by this paper
• Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice

  2021cited by this paper
• Pharmacology of the WNT Signaling System

  2021cited by this paper
• Alzheimer’s Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies

  2020cited by this paper
• Effects of Chronic Administration of Pioglitazone on Learning and Memory in Rat Model of Streptozotocin-induced Alzheimer’s Disease

  2020cited by this paper
• Intranasal insulin administration may be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance

  2020cited by this paper
• Are thiazolidinediones a preferred drug treatment for type 2 diabetes?

  2020cited by this paper
• Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

  2020cited by this paper
• Neuroprotective effects of vildagliptin on drug induced Alzheimer's disease in rats with metabolic syndrome: Role of hippocampal klotho and AKT signaling pathways.

  2020cited by this paper
• Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status

  2020cited by this paper
• Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: the Receptor for Advanced Glycation End Products (RAGE)

  2020cited by this paper
• Glibenclamide modulates microglial function and attenuates Aβ deposition in 5XFAD mice.

  2020cited by this paper
• Glibenclamide as a neuroprotective antidementia drug

  2020cited by this paper
• Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages

  2020cited by this paper
• Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway

  2020cited by this paper
• Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?

  2020cited by this paper
• Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities.

  2020cited by this paper
• Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes

  2020cited by this paper
• Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

  2020cited by this paper
• Intranasal insulin administration may be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance

  2020cited by this paper
• The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation

  2020cited by this paper
• Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study.

  2020cited by this paper
• Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1–42 induced toxicity, in vitro

  2019cited by this paper
• Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer’s Disease

  2019cited by this paper
• Molecular Mechanisms of Intranasal Insulin in SAMP8 Mice

  2019cited by this paper
• Neuronal Calcium Sensor Dream Interactions with Insulinotropic Agent Repaglinide

  2019cited by this paper
• Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse

  2019cited by this paper
• Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

  2019cited by this paper
• Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer’s disease and type 2 diabetes

  2019cited by this paper
• Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease

  2019cited by this paper
• Liraglutide and a lipidized analog of prolactin‐releasing peptide show neuroprotective effects in a mouse model of &bgr;‐amyloid pathology

  2019cited by this paper
• Metformin attenuates diabetes‐induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance

  2019cited by this paper
• DIABETES DRUGS IN THE FIGHT AGAINST ALZHEIMER'S DISEASE.

  2019cited by this paper
• Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β.

  2019cited by this paper
• Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts

  2019cited by this paper
• Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer’s Disease

  2019cited by this paper
• Glibenclamide ameliorates the disrupted blood–brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome

  2019cited by this paper
• Nateglinide Exerts Neuroprotective Effects via Downregulation of HIF-1α/TIM-3 Inflammatory Pathway and Promotion of Caveolin-1 Expression in the Rat’s Hippocampus Subjected to Focal Cerebral Ischemia/Reperfusion Injury

  2019cited by this paper
• Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway

  2019cited by this paper
• The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice

  2019cited by this paper
• Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease

  2019cited by this paper
• Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis

  2018cited by this paper
• Inhibition of the Neuronal Calcium Sensor DREAM Modulates Presenilin-2 Endoproteolysis

  2018cited by this paper
• Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

  2018cited by this paper
• Metformin: An Old Drug with New Applications

  2018cited by this paper
• Possible role of DPP4 inhibitors to promote hippocampal neurogenesis in Alzheimer’s disease

  2018cited by this paper
• GLP‐1 receptor agonists downregulate aberrant GnT‐III expression in Alzheimer's disease models through the Akt/GSK‐3&bgr;/&bgr;‐catenin signaling

  2018cited by this paper
• World Alzheimer report 2018

  2018cited by this paper
• Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta‐analysis

  2018cited by this paper
• Neuroprotective effect of linagliptin against cuprizone‐induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF‐&kgr;B signalling pathway modulation

  2018cited by this paper
• Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

  2018cited by this paper
• Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease

  2018cited by this paper
• ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease.

  2018cited by this paper
• The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease

  2018cited by this paper
• Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease.

  2017cited by this paper
• Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.

  2017cited by this paper
• Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.

  2017cited by this paper
• Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications

  2017cited by this paper
• Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation

  2017cited by this paper
• Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial

  2017cited by this paper
• Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.

  2017cited by this paper
• Astrocyte lipid metabolism is critical for synapse development and function in vivo

  2017cited by this paper
• Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer’s Disease

  2017cited by this paper
• Molecular Interaction of Anti‐Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Co‐Transporter 2

  2017cited by this paper
• Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study

  2017cited by this paper
• Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

  2017cited by this paper
• Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.

  2017cited by this paper
• Pioglitazone for the treatment of Alzheimer’s disease

  2017cited by this paper
• Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model

  2017cited by this paper
• Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer’s disease-like tau pathology

  2017cited by this paper
• Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

  2017cited by this paper
• Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice

  2017cited by this paper
• Identification of repaglinide as a therapeutic drug for glioblastoma multiforme.

  2017cited by this paper
• Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness

  2017cited by this paper
• SGLT2‐inhibitor and DPP‐4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD‐induced obese rats

  2017cited by this paper
• Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease

  2016cited by this paper
• Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial

  2016cited by this paper
• Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy

  2016cited by this paper
• Glimepiride protects neurons against amyloid-β-induced synapse damage.

  2016cited by this paper
• Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease

  2016cited by this paper
• Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans.

  2016cited by this paper
• Differential metformin dose-dependent effects on cognition in rats: role of Akt

  2016cited by this paper
• In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

  2016cited by this paper
• Intranasal administration of Exendin-4 antagonizes Aβ31–35-induced disruption of circadian rhythm and impairment of learning and memory

  2016cited by this paper
• Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction

  2016cited by this paper
• Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.

  2016cited by this paper
• Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

  2016cited by this paper
• The effect of the glycolipoprotein extract (G‐90) from earthworm Eisenia foetida on the wound healing process in alloxan‐induced diabetic rats

  2016cited by this paper
• The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia

  2016cited by this paper
• PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice.

  2016cited by this paper
• Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation.

  2016cited by this paper
• Pioglitazone.

  2016cited by this paper
• Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons

  2016cited by this paper
• Intranasal Insulin Prevents Anesthesia-Induced Spatial Learning and Memory Deficit in Mice

  2016cited by this paper
• Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide

  2016cited by this paper
• Forxiga (dapagliflozin): Plausible role in the treatment of diabetes‐associated neurological disorders

  2016cited by this paper
• Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease

  2015cited by this paper
• Metformin Treatment Alters Memory Function in a Mouse Model of Alzheimer's Disease

  2015cited by this paper

• Relationship between Alzheimer's Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms.

  2025cites this paper
• High-Fat Diet-Induced Obesity Increases Brain Mitochondrial Complex I and Lipoxidation-Derived Protein Damage

  2024cites this paper
• Changes in Paraoxonase, β-Glucosidase, and Carbonic Anhydrase Enzymes Related to Age and Scopolamine-Induced Memory Impairment in Rats

  2024cites this paper
• Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms

  2024cites this paper
• Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease

  2024cites this paper
• Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges.

  2024cites this paper
• Islet amyloid polypeptide fibril catalyzes amyloid-β aggregation by promoting fibril nucleation rather than direct axial growth.

  2024cites this paper
• Repurposing metabolic regulators: antidiabetic drugs as anticancer agents

  2024cites this paper
• From Glucose to Neuroprotection: Exploring Antidiabetic Medications as a Novel Approach to Alzheimer's Disease Treatment

  2024cites this paper
• Exploring DPP IV inhibitors for Alzheimer's disease: Bridging diabetes and neurodegeneration.

  2024cites this paper
• The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients

  2024cites this paper
• Therapeutic Effects of Metformin on Central Nervous System Diseases: A Focus on Protection of Neurovascular Unit

  2024cites this paper
• Empagliflozin ameliorates olfactory bulbectomy-induced depression by mitigating oxidative stress and possible involvement of brain derived neurotrophic factor in diabetic rats

  2024cites this paper
• Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?

  2024cites this paper
• Alzheimer’s Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models)

  2024cites this paper
• Non-canonical Pathways Associated to Amyloid Beta and Tau Protein Dyshomeostasis in Alzheimer's disease: a narrative review.

  2024cites this paper
• Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review

  2023cites this paper
• Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease

  2023cites this paper